vTv Therapeutics is a holding company. Through its subsidiary, vTv Therapeutics LLC, Co. is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Co. has a pipeline of small molecule clinical and pre-clinical drug candidates. Co.'s primary program is TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes. In addition to the studies of TTP399, Co. is conducting a Phase 1 mechanistic study of TTP399 in patients with type 1 diabetes to determine the impact of TTP399 on ketone body formation during a period of acute insulin withdrawal. The VTVT average annual return since 2015 is shown above.
The Average Annual Return on the VTVT average annual return since 2015 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether VTVT average annual return since 2015 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the VTVT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|